The hope for eradicating deadly brain tumors now comes in the form of nasal drops скачать в хорошем качестве

The hope for eradicating deadly brain tumors now comes in the form of nasal drops

Nasal drops with a novel nano-sized medicine are shown to eradicate deadly brain tumors in mouse models with glioblastoma. Glioblastoma tumors form from brain cells called astrocytes and are the most common kind of brain cancer, affecting roughly three in 100,000 people in the United States. Glioblastoma generally progresses very quickly and is almost always fatal. There are no curative treatments for the disease, in part because delivering medicines to the brain remains extremely challenging. “We wanted to change this reality and develop a noninvasive treatment that activates the immune response to attack glioblastoma,” said Alexander Stegh, PhD, Research Director of The Brain Tumor Center at Siteman Cancer Center and Washington University School of Medicine in St. Louis. Intranasal therapy for medication delivery to the brain has been explored before, but this is the first time nanoscale therapies are used to activate immune responses against brain cancers. The precisely engineered structures in nasal drops deliver potent tumor-fighting medicine. "A novel nano medicine that we call spherical nucleic acids, or SNAs," said Stegh. "Gold nanoparticles are conjugated with a corona of little snippets of DNA that mimic foreign tumor-derived DNA. Our SNAs get into cells more effectively, activate the pathway more robustly and most importantly, the little snippet of DNA can be used in noninvasive delivery approaches." The SNAs activate a signaling pathway to produce powerful immune signals that can reprogram the immune system from a standby state to an active tumor-fighting state. When the SNAs are combined with existing immunotherapies, including checkpoint inhibitors, Stegh said longterm survival occurred in a large percentage of animal subjects, including the eradication of glioblastoma. With more preclinical studies planned, Stegh expects enrollment for human clinical trials in the next three to four years at the Brain Tumor Center at Siteman Cancer Center. Subscribe now ➤ https://bit.ly/2NNQiyM For more great content from HEC Media check us out at: Facebook ➤ http://bit.ly/1WPZEek Twitter ➤ http://bit.ly/22qZDNU Instagram ➤ http://bit.ly/1THSOnM